VIRI - Earnings call transcript Q2 2021 | Dogwood Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning, and welcome to Virios Therapeutics Second Quarter 2021 Financial Results Conference Call. Please be advised that today’s call is being recorded at the company's request. At this time, I'd like to turn the call over to Angela Walsh, SVP Finance, Treasurer of Virios Therapeutics. Please proceed, Angela.

Angela Walsh

Thank you. thank joining and conference on everyone call. morning you us for today's Good

update to today of to with Therapeutics are the operational be We pleased made have you with you available to release note an our financial website. on then financial brief call is with during that today's providing as progress financial Duncan, we now with six second And on results, to Please our well results. during you our press review as progress Greg months results, start CEO, provide first quarter. update the XXXX. quarter quarter corporate Virios the on discuss our a We'll our past second return I’ll

Mike of portion our Ralph Dr. In Gendreau call. and Operations with question-and-answer the addition VP our of for the us Grosswald, Medical are Chief Officer

now as update and subsequent results disclaimer filings with required obligation other pleasure in Duncan. to Reform our Greg? SEC. materially. forward-looking current I'd turn company's call meaning that Before statements actual my Litigation morning is CEO, Securities Factors to over will the issued like to any differ XXXX, that today, results and law. statements can disclaim to are these forward-looking cause and the to this forward-looking uncertainties made conference of statements and include we in Please remind as within see the forward-looking release the by of which involves financial only than Act Greg during we Private this made statements risks Any our the call It everyone begin, of Risk the the statements

Greg Duncan

of known. of as as this us We Fibromyalgia X call substantial since progress the update. good to patients will reduction, quarterly our that Angela. endpoint We final this and our reconfirm trial more our expert authorities be time before IMC-X in intervals we're participants Simplex more, the Phase to two recruiting made regulatory morning, permitted or our in top-line in on Trial study much, the am with stands and Xb for toxicology appreciate dose pain I chronic last the will landmark program to to complete of for XX chronic of Fibromyalgia to planned. X we FORTRESS for will guidance formally In FORTRESS program. report so HSV-X Under assess endpoint able we Phase Xb mid-XXXX. propose is Xb the operational Based an one which in ends, we Suppression approved pleased by year to our sites today, plan FORTRESS In are progressing in the toxicology Fibromyalgia the studies we that The These Phase do you timed very the the be required dosed FORTRESS a study our studies as been we to the species with parallel on joining very that trial, are trial back over which by to leadership to Finance, are ongoing refer the used on update Angela our everyone. me six Phase Vice using focus President that cash company prior patients. on primary the And brief Xb operational announcement FORTRESS discuss Therapeutics Fibromyalgia financial the program Type X our Virios has report Research a turn that our months of on planned we’re Fibromyalgia you XXXX, provide you Phase expect The trial FDA team or pleased progress, end top-line of the of May, that let can trial. runway the update And to treatments reaffirming we trial, it's provide progress, the to Phase all we’re results. finally, Synergistic results FDA with Herpes actively Walsh clinical conclusion fully With Outcome team, first operational patient from to-date. all as our it our participating trial to should current QX Evaluating current to our has this Thank results from full at following Senior the study. Angela? the trial. to

Angela Walsh

with Thank our today you, cash position. Greg. I’ll begin

XX, of as cash compared June XXXX. of to XX, million had in XXXX million As December $XX.X $XX.X we as

XXXX company. the We being a net increase company's $X.X cash did be for in not with of quarter XXXX mentioned, attributable our in primarily drug just primarily turn or manufacturing XX, for the chronic reported million Greg was $X.X June for We ended I'll million We quarter. for research year-ago for our XX, as expenses the year-ago the XXXX compared quarter income for stage the the This development costs our June general public generate and loss costs. year-ago to FORTRESS to and development months statement, we research second million reported attributable a a $X.X as our end With in reported now general quarter. over net This the Greg. back loss respect second of XX, compared was ended toxicology development we fund expenses sufficient of during quarter. development through and June million quarter revenue the to XXXX to expenses to call expenses year-ago quarter. ended June to clinical the As to three to and administrative operations second company, of the and and program current $X.XX Greg? administrative ended million expect associated $X.X the million trial, to increase expenses XX, for a XXXX. of $X.X compared

Greg Duncan

potential new Disorders. role a to activated Fibromyalgia in unique Thank evidence potential once like FDA disorders catalyst Herpes which other be Fibromyalgia, supported Syndrome treat a IMC-X approach data, represents can antiviral dose in best and is track our the HSV-X existing knowledge expect has in diseases Fibromyalgia to synergistic the range as related new been and a a the The to to programs second Angela. the this of treating candidate half said to drug community chronic Fibromyalgia virus this research plans to completely you approach again, activated lead our of our program The Fibromyalgia, role potentially triggering and and of a IMC-X fixed unique mechanism of time designation Fibromyalgia, for both GI bowel of increasing the by seen review exploring the mechanistic during of by fast granted We're of wide candidate this clinical fatigue of an represents is Somatic feasibility timing first complement communicate treatment. morbidities the viruses there disorders. designation and like recognition Encouragingly, actively HSV-X scientific the including syndrome, irritable executing and additional of the year. granted targeted

to the medical of as as treatment across ready We’re as frequent to community our patients journey now progress of standards for Operator, the the investment community, and committed hundreds we to fibromyalgia outreach globe. try for we’re questions. millions well proactive and improve

Operator

Small-Cap our floor now open Instructions]. ahead. first The Research. Zacks for is Please Bautz take with you. question We'll go [Operator from David Thank questions.

David Bautz

of morning, cases increase with around in any in enrollment, drop everyone. the off I'm COVID curious good terms patient the country? of have Hey, recent type you seen

Greg Duncan

Duncan. in question. sites that today. I'll thank enough, progressed is mentioned all as This take David. Hi, first our you Greg call with And we Interestingly operational. getting joining have for I the of

experience and enrolled believe really over have the Based the changes few was COVID. we've first experience months going had during slightly to one pace outbreak Fibromyalgia experience, nice the per over it categories actually I on clinical in teams patients XXX progressed anticipate year a based on. the We the last prior se do enrollment trial we on our rate COVID. not of few in team's as the and the that -- first Research major a

the reflected quite own will severity care that. the an that of And eye standard. to their the their disease these that's pain, on significant. with but a And experience, I fatigue, so as up mortality that, is the really the not committed is quite can to And improve result, in getting we’re are based patients the we disease, keep continue certainly on morbidity, patients think show reason prior associated these forecasting

it, So have while on we're seen eye delays sort any but not David. to-date, keep of we an forecasting, we’re not

David Bautz

Okay, great.

about into basically, what you Now goes taking will wondering in bit determining terms plan talk be? of other programs the that you was into clinic. I next little a could programs those what just on And if

Greg Duncan

syndrome, Fibromyalgia, impetus to Syndrome using question. Somatic Yes, fatigue moving on Founder disorders. combination Somatic related The Dr. based for experience therapies our so irritable the is Disorders like bowel Disorders Syndrome treat into William in Pridgen of antiviral and excellent

Herpes reached can of see work was with We a will February well actually where the are and has Xa of the And you Type we different Simplex particular top Fibromyalgia in our look that related Clinic or is X syndrome study design the in reasons, you to of a fatigue postulated Phase also announced proof-of-concept disorders. collaboration implicated to our at selected the diseases. Dr. experienced In notably come behind irritable a been research hypothesized And involved these as you're particular, Herpes to in be Mayo different that this if number with founders prior patients. queue Camilleri diseases. determine bowel in Simplex literature X Michael medical to bowel aware, in of probably and two irritable for number syndrome, a and have

was Type that highlighted the of Meeting recall Herpes the You activation today's in GI presented Chronic X spring, Digestive may of DDW Alabama Week that Simplex biopsy tissue disorders. the at study University Disease actually in

it's tie bowel there been safe data that think is marketplace. been is at in a irritable IBS like I the in in people significant gets meetings. that's unmet there's assessing hope to published. So treatment, there that And say We that postulated, need most much it's scientific Note Fibromyalgia. mechanistic syndrome presented

Xa us to reduced we from the Fibromyalgia retreat potential IMC-X So excellent for an trial And IBS significantly pain. with great provides a which this Phase of related pain, would I signal that target. mention IMC-X utility is our believe

evidence are other chronic the related whether root is and amongst potentially are being cause related symptom mechanism The of that potential includes is those particular really replicating disorders. it that know, suggests that or that through may a COVID need. another may seeing immune system fatigue cetera, that's looking therapies be Type and right as fatigue also you exploring it's recent the consequence, fatigue for at area increasing utility to a not as Coronavirus And that These patients as activated who symptom the the breaking an that a in Herpes we're the one are literature number viruses, actually And other long-holder particular other might syndrome. area desperate provide not et potential there may now, by fatigue of because And emerging population. the this And disorders breakthrough medical we're space Epstein-Barr, that implicated Simplex X as Coronavirus. gets see medical challenged literature some are for the in manifestation. you're the be

as back will mentioned David? Program. that So year. be Landmark we for to of as the back brief report at Fibromyalgia our the on the we just your is the the that areas update we to Does to answers the in half yourself those update And upshot, progress this in programs second particular investment like plans after community complements question, folks

David Bautz

that. Do I And of theory Yes, What you you. in of have get get one What field meetings, Thank does. kind of I'm at experts and the when on scientific viral you other I just to you curious. kind kind driven are follow-up there? interactions this pushback? propose disorders? it reception going idea? Fibromyalgia the this open of Yes, chronic mean, KOLs and

Greg Duncan

great Yes, it’s David. question, a

Dr. went Dr. for and years In will years. to you, De will dark, Rosa, they ago, Abel tell La board you and fact, these many, they research were you theses kind if members, if talk our on Rich of many many trained the Whitley

hypothesis. to this whole the I've test neurologists is And not so that a this have pursuing trained that. it Virios pursued hypothesis. Therapeutics unfortunately, And was there's been been that contingent And actually on looking vigor of with

to uniqueness as Syndrome areas be treatment pretty first it's referenced at and disorders, high in that about other why Fibromyalgia a the Fibromyalgia, see so neurologists, late are that Fibromyalgia, cetera. We consequence, of the think the I And review ever down of designation, our to psychiatrists, thesis question think addition best Disorders the knowledge a actually Xb of that the evidence your actually our for place to thesis. track right sites granted was we folks of BBW, research all-time an viruses fast that helps handful viruses on a the the pain GI interest and in live rheumatologists, because in this is turn to FDA, particular And this, our we like that's virology broader Phase And claim the and the to question accepted the of as which validates evidence in the candidate. to in IMC-X can knowledge. there’s interest what very to And had of case believe I participate et IBS is general knowledge based earlier as great community. we treating of these treat intrigued trial us or Somatic really that we I this are make specialists interest actually now. world believe presentations exciting receptivity impact of to think is breaking biopsy

helps that HSV-X, focused obviously our So we that And on raise on awareness. probably with then to momentum. build general to activities continue hope

David Bautz

Great. Well, you appreciate right. this questions All morning. taking I the Yes.

Greg Duncan

Thank you, Sure. David.

Operator

back no be turn to questions this We'll Sir, remarks. the Duncan it for appear floor is closing at Mr. further to There Instructions] yours. [Operator time.

Greg Duncan

And Karen. attending Yes. for Virios Therapeutics. Thank this you, quarter morning's update all thank you for two

that and truly to where response do, the in suffer novelty antiviral of treat designation, are very drug for with and U.S. evidence millions very suffering novel experience from patients of of there seen we’re a two is from in data, of the in we believe As we're patients literally category epidemiology that market ever track delivering development many approved our to And question. drugs notably, targeting The debilitating are who we And includes Fibromyalgia diseases. can we hundreds combination large a you be pursuing and therapies board Fibromyalgia, mentioned chronic therapies. review here of Fibromyalgia mentioned, fast opportunity has if commercialized I of experience believe approach leading team which David's three the development just commercialization extensive and the to

target think virus fatigue holds or X the Simplex and Somatic syndromes of As great I queue. the Herpes being Disorders, other promise do we mentioned, top inhibition related for of Type HSV-X Syndrome this IBS

Be next in feed second on will the back XX, We plans on much. Small do of certainly this will safe an report you'd presentation the at opportunities and be SNN the our quarter our half to you over Conference Thank keep Investor those update. next updates and and pursue own the eye year. on if news August with in like very dial latest to your various

Operator

for Ladies does and participation. thank you your teleconference. this today's again We conclude gentlemen,

time may a have You disconnect lines and great your this day. at

Dogwood Therapeutics (DWTX) 13 Aug 212021 Q2 Earnings call transcript